Last 12 months
Inside the activity.
0 purchase rows · 83 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 9 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 17 |
| Apr 2026 | 0 | 8 |
| May 2026 | 0 | 9 |
| Jun 2026 | 0 | 8 |
| Jul 2026 | 0 | 9 |
| Aug 2026 | 0 | 4 |
| Sep 2026 | 0 | 8 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 05, 2025 Filed Dec 5, 2025 22:35 UTC |
Callos AndrewEVP, Chief Commercial Officer
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 10,628 | $0.00 Strike: $37.63 | $0.00 |
DisclosureSEC source: 0001061983-25-000048 · form4.xml · derivative · entry 9 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,657 Underlying: Common Stock · 10,628 shares Expires 2032-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 22:35 UTC |
Callos AndrewEVP, Chief Commercial Officer
|
Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 15,858 | $0.00 Strike: $37.63 | $0.00 |
DisclosureSEC source: 0001061983-25-000048 · form4.xml · derivative · entry 8 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,857 Underlying: Common Stock · 15,858 shares Expires 2032-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 22:35 UTC |
Callos AndrewEVP, Chief Commercial Officer
|
Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $39.13 | $0.00 |
DisclosureSEC source: 0001061983-25-000048 · form4.xml · derivative · entry 7 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,445 Underlying: Common Stock · 11,000 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 22:35 UTC |
Callos AndrewEVP, Chief Commercial Officer
|
Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $23.26 | $0.00 |
DisclosureSEC source: 0001061983-25-000048 · form4.xml · derivative · entry 6 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,000 Underlying: Common Stock · 15,000 shares Expires 2031-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 22:35 UTC |
Callos AndrewEVP, Chief Commercial Officer
|
SaleCommon Stock | 52,486 | $65.95 | $3,461,451.70 |
DisclosureSEC source: 0001061983-25-000048 · form4.xml · nonDerivative · entry 5 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,660 Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 22:35 UTC |
Callos AndrewEVP, Chief Commercial Officer
|
Exercise / conversionCommon Stock | 10,628 | $37.63 | $399,931.64 |
DisclosureSEC source: 0001061983-25-000048 · form4.xml · nonDerivative · entry 4 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 22:35 UTC |
Callos AndrewEVP, Chief Commercial Officer
|
Exercise / conversionCommon Stock | 15,858 | $37.63 | $596,736.54 |
DisclosureSEC source: 0001061983-25-000048 · form4.xml · nonDerivative · entry 3 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 22:35 UTC |
Callos AndrewEVP, Chief Commercial Officer
|
Exercise / conversionCommon Stock | 11,000 | $39.13 | $430,430.00 |
DisclosureSEC source: 0001061983-25-000048 · form4.xml · nonDerivative · entry 2 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 22:35 UTC |
Callos AndrewEVP, Chief Commercial Officer
|
Exercise / conversionCommon Stock | 15,000 | $23.26 | $348,900.00 |
DisclosureSEC source: 0001061983-25-000048 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 21:25 UTC |
Lee SungEVP, Chief Financial Officer
|
Tax withholdingCommon Stock | 1,560 | $65.02 | $101,431.20 |
DisclosureSEC source: 0001061983-25-000046 · form4.xml · nonDerivative · entry 1 Lee Sung · CIK 0001793200 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,917 F1 · kind: Sell to cover transaction for tax withholding upon vesting of Performance Stock Units granted earned on December 2, 2024. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 21:23 UTC |
Callos AndrewEVP, Chief Commercial Officer
|
Tax withholdingCommon Stock | 1,368 | $65.02 | $88,947.36 |
DisclosureSEC source: 0001061983-25-000045 · form4.xml · nonDerivative · entry 1 Callos Andrew · CIK 0001852129 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,660 F1 · kind: Sell to cover transaction for tax withholding upon vesting of Performance Stock Units granted on March 14, 2024 and earned December 2, 2024. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 21:20 UTC |
Malik Fady IbrahamEVP Research & Development
|
Tax withholdingCommon Stock | 2,058 | $65.02 | $133,811.16 |
DisclosureSEC source: 0001061983-25-000044 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,552 F1 · kind: Sell to cover transaction for tax withholding upon vesting of Performance Stock Units granted on March 14, 2024 and earned December 2, 2024. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 21:17 UTC |
Blum Robert IDirector · President & CEO
|
Tax withholdingCommon Stock | 5,930 | $65.02 | $385,568.60 |
DisclosureSEC source: 0001061983-25-000043 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,202 Read SEC document |
| December 02, 2025 Filed Dec 2, 2025 22:14 UTC |
HENDERSON JOHN TDirector
|
Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 8,750 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001061983-25-000042 · form4.xml · derivative · entry 4 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,750 shares Expires 2026-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2025 Filed Dec 2, 2025 22:14 UTC |
HENDERSON JOHN TDirector
|
SaleCommon Stock | 8,750 | $63.90 | $559,125.00 |
DisclosureSEC source: 0001061983-25-000042 · form4.xml · nonDerivative · entry 2 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,578 Read SEC document |
| December 02, 2025 Filed Dec 2, 2025 22:14 UTC |
HENDERSON JOHN TDirector
|
Exercise / conversionCommon Stock | 8,750 | $10.00 | $87,500.00 |
DisclosureSEC source: 0001061983-25-000042 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2025 Filed Dec 2, 2025 22:10 UTC |
Malik Fady IbrahamEVP Research & Development
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 2,200 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-25-000041 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,200 Underlying: Common Stock · 2,200 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2025 Filed Dec 2, 2025 22:10 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 2,200 | $63.89 | $140,558.00 |
DisclosureSEC source: 0001061983-25-000041 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,610 Read SEC document |
| December 02, 2025 Filed Dec 2, 2025 22:10 UTC |
Malik Fady IbrahamEVP Research & Development
|
Exercise / conversionCommon Stock | 2,200 | $10.60 | $23,320.00 |
DisclosureSEC source: 0001061983-25-000041 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,810 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 14:18 UTC |
Kaye Edward M. MDDirector
|
Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $14.25 | $0.00 |
DisclosureSEC source: 0001061983-25-000040 · form4.xml · derivative · entry 5 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2027-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 18, 2018. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 14:18 UTC |
Kaye Edward M. MDDirector
|
Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 8,064 | $0.00 Strike: $12.40 | $0.00 |
DisclosureSEC source: 0001061983-25-000040 · form4.xml · derivative · entry 4 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,064 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option shall vest and become exercisable as to 8,064 shares divided into equal monthly installments such that the option shall be 100% vested on January 3, 2018. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 14:18 UTC |
Kaye Edward M. MDDirector
|
SaleCommon Stock | 28,064 | $66.72 | $1,872,430.08 |
DisclosureSEC source: 0001061983-25-000040 · form4.xml · nonDerivative · entry 3 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,977 Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 14:18 UTC |
Kaye Edward M. MDDirector
|
Exercise / conversionCommon Stock | 20,000 | $14.25 | $285,000.00 |
DisclosureSEC source: 0001061983-25-000040 · form4.xml · nonDerivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 14:18 UTC |
Kaye Edward M. MDDirector
|
Exercise / conversionCommon Stock | 8,064 | $12.40 | $99,993.60 |
DisclosureSEC source: 0001061983-25-000040 · form4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 14:13 UTC |
Harrington Robert ArthurDirector
|
SaleCommon Stock | 2,150 | $66.80 | $143,620.00 |
DisclosureSEC source: 0001061983-25-000039 · form4.xml · nonDerivative · entry 1 Harrington Robert Arthur · CIK 0001923988 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,542 Read SEC document |
| November 19, 2025 Filed Nov 19, 2025 23:57 UTC |
PARSHALL B LYNNEDirector
|
SaleCommon Stock | 5,000 | $64.73 | $323,650.00 |
DisclosureSEC source: 0001061983-25-000038 · form4.xml · nonDerivative · entry 1 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,933 Read SEC document |
| November 18, 2025 Filed Nov 18, 2025 21:23 UTC |
Malik Fady IbrahamEVP Research & Development
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 2,200 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-25-000037 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,400 Underlying: Common Stock · 2,200 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2025 Filed Nov 18, 2025 21:23 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 2,200 | $66.45 | $146,190.00 |
DisclosureSEC source: 0001061983-25-000037 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,610 Read SEC document |
| November 18, 2025 Filed Nov 18, 2025 21:23 UTC |
Malik Fady IbrahamEVP Research & Development
|
Exercise / conversionCommon Stock | 2,200 | $10.60 | $23,320.00 |
DisclosureSEC source: 0001061983-25-000037 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,810 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2025 Filed Nov 17, 2025 21:02 UTC |
Hessekiel JeffreyChief Legal & Admin Officer
|
GrantCommon Stock | 87,297 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-25-000036 · form4.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · Chief Legal & Admin Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,297 F1 · kind: Initial new hire grant comprised of restricted stock units ("RSUs") that are convertible to shares of common stock on a 1:1 basis upon vesting. RSUs will vest as follows: 40% of the aggregate RSUs on the date falling 1-year from the date of grant, an additional 40% of the aggregate RSUs on the date falling 2-years from the date of grant, and the remaining 20% of the aggregate RSUs on the date falling 3-years from the date of grant, in each case subject to Mr. Hessekiel's continued employment with Cytokinetics. Read SEC document |
| November 11, 2025 Filed Nov 12, 2025 23:50 UTC |
Kaye Edward M. MDDirector
|
Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 5,175 | $0.00 Strike: $9.66 | $0.00 |
DisclosureSEC source: 0001061983-25-000031 · form4.xml · derivative · entry 3 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,175 shares Expires 2026-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option shall vest and become exercisable as to 5,175 shares divided into equal monthly installments such that the option shall be 100% vested on January 1, 2017. Read SEC document |
| November 11, 2025 Filed Nov 12, 2025 23:50 UTC |
Kaye Edward M. MDDirector
|
SaleCommon Stock | 5,175 | $65.08 | $336,789.00 |
DisclosureSEC source: 0001061983-25-000031 · form4.xml · nonDerivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,977 Read SEC document |
| November 11, 2025 Filed Nov 12, 2025 23:50 UTC |
Kaye Edward M. MDDirector
|
Exercise / conversionCommon Stock | 5,175 | $9.66 | $49,990.50 |
DisclosureSEC source: 0001061983-25-000031 · form4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2025 Filed Nov 5, 2025 21:22 UTC |
Blum Robert IDirector · President & CEO
|
GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-25-000030 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 356,108 Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 00:23 UTC |
Malik Fady IbrahamEVP Research & Development
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 2,295 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-25-000029 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,600 Underlying: Common Stock · 2,295 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 00:23 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 2,295 | $59.55 | $136,667.25 |
DisclosureSEC source: 0001061983-25-000029 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,610 Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 00:23 UTC |
Malik Fady IbrahamEVP Research & Development
|
Exercise / conversionCommon Stock | 2,295 | $10.60 | $24,327.00 |
DisclosureSEC source: 0001061983-25-000029 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,905 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2025 Filed Oct 30, 2025 20:25 UTC |
Blum Robert IDirector · President & CEO
|
SaleCommon Stock | 5,000 | $62.86 | $314,300.00 |
DisclosureSEC source: 0001061983-25-000027 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 358,108 Read SEC document |
| October 27, 2025 Filed Oct 27, 2025 21:59 UTC |
WIERENGA WENDELLDirector
|
Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 4,375 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001061983-25-000026 · form4.xml · derivative · entry 3 WIERENGA WENDELL · CIK 0001239956 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,375 shares Expires 2026-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option shall vest and become exercisable as to 4,375 shares divided into equal monthly installments such that the option shall be 100% vested on January 4, 2017. Read SEC document |
| October 27, 2025 Filed Oct 27, 2025 21:59 UTC |
WIERENGA WENDELLDirector
|
SaleCommon Stock | 4,375 | $58.68 | $256,725.00 |
DisclosureSEC source: 0001061983-25-000026 · form4.xml · nonDerivative · entry 2 WIERENGA WENDELL · CIK 0001239956 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,444 Read SEC document |
| October 27, 2025 Filed Oct 27, 2025 21:59 UTC |
WIERENGA WENDELLDirector
|
Exercise / conversionCommon Stock | 4,375 | $10.00 | $43,750.00 |
DisclosureSEC source: 0001061983-25-000026 · form4.xml · nonDerivative · entry 1 WIERENGA WENDELL · CIK 0001239956 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,819 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 21, 2025 Filed Oct 21, 2025 22:18 UTC |
Malik Fady IbrahamEVP Research & Development
|
Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,105 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-25-000025 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 2,105 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 21, 2025 Filed Oct 21, 2025 22:18 UTC |
Malik Fady IbrahamEVP Research & Development
|
SaleCommon Stock | 2,105 | $58.22 | $122,553.10 |
DisclosureSEC source: 0001061983-25-000025 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,610 Read SEC document |
| October 21, 2025 Filed Oct 21, 2025 22:18 UTC |
Malik Fady IbrahamEVP Research & Development
|
Exercise / conversionCommon Stock | 2,105 | $10.60 | $22,313.00 |
DisclosureSEC source: 0001061983-25-000025 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,715 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 16, 2025 Filed Oct 16, 2025 21:05 UTC |
Blum Robert IDirector · President & CEO
|
SaleCommon Stock | 5,000 | $60.03 | $300,150.00 |
DisclosureSEC source: 0001061983-25-000016 · form4.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 363,108 Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 20:36 UTC |
HENDERSON JOHN TDirector
|
GrantCommon Stock | 338 | $62.80 | $21,226.40 |
DisclosureSEC source: 0001061983-25-000012 · form4.xml · nonDerivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,578 F1 · kind: Director equity in lieu of cash retainer program. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 20:37 UTC |
Harrington Robert ArthurDirector
|
GrantCommon Stock | 199 | $62.80 | $12,497.20 |
DisclosureSEC source: 0001061983-25-000013 · form4.xml · nonDerivative · entry 1 Harrington Robert Arthur · CIK 0001923988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,692 F1 · kind: Director equity in lieu of cash retainer program. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 20:34 UTC |
Kaye Edward M. MDDirector
|
GrantCommon Stock | 199 | $62.80 | $12,497.20 |
DisclosureSEC source: 0001061983-25-000011 · form4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,977 F1 · kind: Director equity in lieu of cash retainer program. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 20:32 UTC |
Wysenski NancyDirector
|
GrantCommon Stock | 99 | $62.80 | $6,217.20 |
DisclosureSEC source: 0001061983-25-000010 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,873 F1 · kind: Director equity in lieu of cash retainer program. Read SEC document |
| October 15, 2025 Filed Oct 21, 2025 16:22 UTC |
WIERENGA WENDELLDirector
|
GrantCommon Stock | 99 | $62.80 | $6,217.20 |
DisclosureSEC source: 0001061983-25-000024 · form4.xml · nonDerivative · entry 1 WIERENGA WENDELL · CIK 0001239956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,444 F1 · kind: Director equity in lieu of cash retainer program. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.